Actinium Pharmaceuticals
ATNM
74 hedge funds and large institutions have $53.6M invested in Actinium Pharmaceuticals in 2024 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 28 increasing their positions, 16 reducing their positions, and 11 closing their positions.
75% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 16
73% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 11
70% more call options, than puts
Call options by funds: $1.07M | Put options by funds: $629K
10% more funds holding
Funds holding: 67 → 74 (+7)
2% more capital invested
Capital invested by funds: $52.8M → $53.6M (+$847K)
0.04% more ownership
Funds ownership: 24.3% → 24.34% (+0.04%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$1.37M |
| 2 |
SSA
Schonfeld Strategic Advisors
New York
|
+$1.17M |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$853K |
| 4 |
N
Nuveen
Charlotte,
North Carolina
|
+$583K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$581K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$730K |
| 2 |
VF
Virtu Financial
New York
|
-$503K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$466K |
| 4 |
Verition Fund Management
Greenwich,
Connecticut
|
-$460K |
| 5 |
Millennium Management
New York
|
-$382K |
ATNM Hedge Fund Activity: Q2 2024 in Review
74 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Actinium Pharmaceuticals (ATNM) for Q2 2024, worth a combined $53.6M — up 1.6% from $52.8M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new ATNM positions and 11 closed out — a net gain of 8 holders — while 28 added to existing stakes and 16 trimmed.
The largest buyer was BlackRock, adding an estimated $1.37M. The largest seller was Hudson Bay Capital Management, exiting entirely with an estimated $730K sold.
- 74 institutional investors held Actinium Pharmaceuticals (ATNM) as of Q2 2024, up from 67 in Q1 2024.
- Funds reported $53.6M of Actinium Pharmaceuticals stock for Q2 2024, up 1.6% quarter-over-quarter.
- 19 funds opened new Actinium Pharmaceuticals positions in Q2 2024 and 11 closed out, a net change of +8 holders.
- The largest Actinium Pharmaceuticals buyer in Q2 2024 was BlackRock, an estimated $1.37M added.
- The largest Actinium Pharmaceuticals seller in Q2 2024 was Hudson Bay Capital Management, an estimated $730K sold.
Based on aggregated 13F filings for Q2 2024.